Abstract: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
October 5, 2010
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Sweet Raymond
Abstract: An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds to one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.
Type:
Grant
Filed:
June 26, 2007
Date of Patent:
October 5, 2010
Assignee:
Centocor Ortho Biotech, Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Jeffrey (Sinquan) Luo
Abstract: Methods for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis administer IL-16 antagonists, for example, anti-IL-16 antibodies, to subjects.
Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
June 15, 2010
Assignee:
Centocor, Inc.
Inventors:
Jin Lu, Thomas Nesspor, Bernard Scallon, Linda Snyder
Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
July 14, 2009
Assignees:
Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.
Inventors:
Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
Abstract: Isolated nucleic acids encoding an anti-IL-12 antibody or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
Type:
Grant
Filed:
January 29, 2007
Date of Patent:
July 14, 2009
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
Abstract: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Type:
Grant
Filed:
June 30, 2006
Date of Patent:
February 17, 2009
Assignee:
Centocor, Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Sweet Raymond
Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
January 20, 2009
Assignee:
Centocor, Inc.
Inventors:
Xiao-yu R. Song, Chong Huang, Keying Ma, Bailin Liang, Michael Naso
Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.
Type:
Grant
Filed:
April 30, 2004
Date of Patent:
February 5, 2008
Assignee:
Centocor, Inc.
Inventors:
Xiao-Yu Song, Chris Huang, Keying Ma, Bailin Liang, Michael Naso
Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
October 28, 2004
Date of Patent:
October 9, 2007
Assignee:
Centocor, Inc.
Inventors:
Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
Abstract: An anti-IL-23 specific human Ig derived protein is useful in therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably includes one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.
Type:
Grant
Filed:
September 23, 2005
Date of Patent:
August 7, 2007
Assignee:
Centocor, Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Jeffrey Luo
Abstract: Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.
Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
October 28, 2004
Date of Patent:
June 20, 2006
Inventors:
Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
Abstract: The present invention relates to at least one anti-IL-12 antibody, including isolated nucleic acids that encode at least one anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
June 7, 2005
Assignee:
Centocor, Inc.
Inventors:
Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
Abstract: An intravenous pharmaceutical composition comprising an aqueous solution of arsenic trioxide and sodium chloride. The composition is effective in the treatment of cancers including leukemia. Complete remission of up to 21 years have been observed for acute promyelocytic leukemia patients.
Abstract: An apparatus for retaining and controlling the size of pieces of snow and/or ice accumulating on a roof contains brackets secured to the roof and rails passed between the brackets to form a frame structure. The brackets have slots and/or pockets for fitting rails and enable the rails to be at or below the level of seams on seamed roofs and at a low profile with non-seamed roofs. In addition, the brackets may be attached to the roof without penetrating the roof structure. A method of installing a snow and/or ice retaining apparatus includes lowering the rails into pockets on the brackets, sliding the rails into slots on the brackets, and, optionally, securing the rails with a clip, wedge, or adhesive.